VIRAL VECTORS AND VACCINES

CELL LINES FOR

Specifically designed for the purpose of Adenoviral vector production, CEVEC’s proprietary CAP® Ad Platform based on human suspension cells is the ideal production platform for the manufacturing of RCA-free Adenoviral vectors from research up to industrial scale.

MOVE TO AN
RCA-FREE ADENOVIRUS PRODUCTION PROCESS
RIGHT FROM THE START

HUMAN CELL LINE

Non-tumor cell line derived from human amniocytes

FULLY DOCUMENTED

Complete documentation of cell line development and full certification of materials

HIGH SCALABILITY

Suspension cell line growing at high cell densities for high yields

FULLY TESTED

GMP MCB tested according to ICH guidelines and WHO recommendations. Biologics Master File on file at U.S. FDA

In addition to Adenoviral vectors, CAP® cells have also proven to be an efficient host cell line for the production of viral vaccines, Lentiviral vectors, Oncolytic viruses, and Exosomes.

HOW TO GET ACCESS TO OUR TECHNOLOGY AND SERVICES

We offer cell line development services to adapt the CAP® cell line to your specific needs and provide extensive technical support to perform evaluation studies with your Ad vector of choice. Furthermore, specific license models are available for the use of the CAP® Ad Platform for manufacturing at different scales and for various applications.

Transfer of cells

CEVEC provides the CAP® cells as well as all required cultivation protocols, methods and processes.

Technology Transfer

A full in person technology transfer is done at the production site.

GMP Production

CEVEC provides access to GMP-grade cell banks (MCB and WCB) with full documentation and large-scale upstream & downstream production protocols.

Licensing

Subject to the execution of an individualized R&D, clinical or commercial license, CEVEC assists to select the appropriate CDMO partner enabling a smooth technology transfer.

Regulatory Support

For dossier filings with regulatory agencies, CEVEC provides CAP® related support.

© CEVEC Pharmaceuticals GmbH 2021